Pemigatinib, an FGFR inhibitor, overcomes resistance to KRASG12C inhibitors in mesenchymal-like NSCLC tumors

被引：0
|
作者：
Favata, Margaret
Weber, Michael
Abdollahi, Angela
Roman, Valerie Dostalik
Farren, Matt
Gilmartin, Aidan
Kim, Sunkyu
Wee, Susan
Rios-Doria, Jonathan
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-430
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
430
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors
    Gu, Shaoulai
    Li, Qiang
    Li, Chao
    Wang, Qixin
    Fang, Douglas D.
    Wang, Shaomeng
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2022, 82 (12)
  • [32] Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis
    Dang, Shoutao
    Zhang, Shuyang
    Zhao, Jingyang
    Li, Wei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [33] Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R
    Qi, Wei-liang
    Li, Hui-yu
    Wang, Yi
    Xu, Lan
    Deng, Jie-ting
    Zhang, Xi
    Wang, Yu-xiang
    Meng, Ling-hua
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (05) : 1083 - 1094
  • [34] Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R
    Wei-liang Qi
    Hui-yu Li
    Yi Wang
    Lan Xu
    Jie-ting Deng
    Xi Zhang
    Yu-xiang Wang
    Ling-hua Meng
    Acta Pharmacologica Sinica, 2023, 44 : 1083 - 1094
  • [35] Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells
    Lee, Chaeyoung
    Yi, Jawoon
    Park, Jihwan
    Ahn, Byungyong
    Won, Young-Wook
    Jeon, Jiheung
    Lee, Byung Ju
    Cho, Wha Ja
    Park, Jeong Woo
    CELL DEATH & DISEASE, 2024, 15 (01)
  • [36] Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells
    Chaeyoung Lee
    Jawoon Yi
    Jihwan Park
    Byungyong Ahn
    Young-Wook Won
    JiHeung Jeon
    Byung Ju Lee
    Wha Ja Cho
    Jeong Woo Park
    Cell Death & Disease, 15
  • [37] Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
    Chen, Qi-An
    Lin, Wei-Hao
    Zhou, Xiao-Xiang
    Cao, Zheng
    Feng, Xiao-Li
    Gao, Yi-Bo
    He, Jie
    PHARMACOLOGICAL RESEARCH, 2024, 200
  • [38] The gRAss Is Greener: Potential new Therapies in Lung cancer with Acquired Resistance to KRAsG12c Inhibitors
    Pinnelli, Marika
    Trusolino, Livio
    CANCER DISCOVERY, 2021, 11 (08) : 1874 - 1876
  • [39] Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
    Jazieh, Khalid
    Tsai, Jill
    Solomon, Sheila
    Zhu, Mojun
    Sinicrope, Frank A.
    Pedersen, Katrina S.
    Fernandez-Zapico, Martin E.
    Xie, Hao
    CLINICAL CANCER RESEARCH, 2025, 31 (05) : 899 - 906
  • [40] NT219, a dual inhibitor of IRS1/2 and STAT3, suppresses cancer stem cell mediated resistance to KRASG12C and KRASG12D inhibitors in solid tumors
    Reuveni, Hadas
    Al-Hallak, Mohammed Najeeb
    Motorwala, Sarah
    Beal, Eliza
    Kim, Steve
    Beydoun, Rafic
    Dyson, Gergory
    El-Rayes, Bassel
    Chen, Herbert
    Philip, A. Philip
    Shields, Anthony F.
    Pasche, Boris
    Sigalov, Katy
    Ben-David, Hava
    Miron, Daphna
    Azmi, Asfar S.
    CANCER RESEARCH, 2024, 84 (06)
12345